Suitability depends on the condition, cell type, plans permitted under Korean law, and an individual assessment. The EHL team reviews your health information and explains the available options before confirming a care plan.
A cell product is not like a tablet that can be reproduced identically every time. Cells are living material that respond to culture conditions, so safety depends heavily on the quality system. GMP requires controlled facilities, trained personnel, written procedures, release testing and traceable documentation. Release testing typically includes cell count and viability, surface markers, testing for bacteria, fungi and mycoplasma, and endotoxin levels. When a provider quotes cell numbers in the millions but cannot show quality documentation, that number tells you almost nothing about safety. EHL BIO publishes information about its GMP centre in the R&D section of its website, where readers can verify the details at the source.
Source: EHL BIO — GMP center
Experts behind this content
EHL Thailand Medical Information Team — Evidence levels, regulatory status, and separating hospital information from medical information
EHL BIO scientific information is compiled alongside public information from its research team and GMP centre. See the full expert panel